Background. Routinely, the first measles, mumps, and rubella (MMR) vaccine dose is given at 14 months of age in the Netherlands. However, during a measles epidemic in 2013-2014, MMR vaccination was also offered to 6-14-month-olds in municipalities with <90% MMR vaccination coverage. We studied the effectiveness of the early MMR vaccination schedule.
Measles is a highly contagious viral disease. It can lead to severe illness and even death, with the greatest burden in the youngest children [1, 2] . Most deaths from acute measles are due to secondary infections resulting from measles-induced suppression of immune responses [3] . Measles vaccination programs have led to a large decline in global mortality, from an estimated 562 400 annual measles deaths in 2000 to 114 900 in 2014 [4] .
Infants aged <1 year were at highest risk of measles in recent outbreaks in Europe [5, 6] . This is worrisome because the risk of measles-associated complications and case-fatality rates are highest among infants [2, 7] . Passively acquired maternal antibodies protect infants against measles during the first months of life. However, infants of vaccinated women have significantly lower concentrations of maternal antibodies than infants of naturally immune women [8] , and protection is on average 2-3 months shorter [8, 9] . At the age of 6 months, most infants (95% born to naturally immune women and 99% born to vaccinated women) lack detectable maternal antibodies [8] .
The World Health Organization advises delivering the first dose of measles, mumps, and rubella (MMR) vaccine to infants aged 9 months in measles-endemic countries and to infants aged 12 months in countries with low rates of measles transmission [10] . In the Netherlands, children are offered MMR vaccination at 14 months and 9 years of age. Infants who have lost their protection from maternal antibodies are susceptible until their first vaccination. Administering vaccinations at an earlier age than 9 months may be beneficial when the risk of measles is high.
However, measles vaccination of infants <9 months of age has been associated with lower proportions of children who develop protective antibody levels after measles vaccination. The median proportion of children who seroconverted after measles vaccination at 8-9 months of age was 90% (interquartile range [IQR] , 82%-95%) among 44 studies, while the median was 99% (IQR, 93%-100%) among infants vaccinated at 11-12 months in 21 studies [11] . However, the majority of these studies were conducted in developing countries. Seroconversion results stratified by age may be different in industrialized countries. Reasons for this include lower levels of maternal antibodies, since most mothers have vaccine-induced immunity to measles only. In a study where infants were included without maternal antibodies, no differences were found in the seroconversion rates for infants vaccinated at 9 and 12 months of age [12] .
In a systematic review of case-control and cohort studies, the effectiveness against laboratory-confirmed measles of a 1-dose measles-containing vaccine (MCV) administered at the age of 9-11 months was estimated to be 84%, while the vaccine effectiveness (VE) for infants who were vaccinated at the age of ≥12 months was 93% [13] . VE estimates for infants vaccinated at <9 months of age are scarce. In a retrospective cohort study in Niger in 1995, a single dose of MCV administered to infants aged <9 months resulted in a VE of 87% (95% CI, 81%-91%) against self-reported clinical measles among children 6-59 months of age [14] . To date, no VE estimates against laboratory-confirmed measles have been reported in observational studies among infants vaccinated at <9 months of age. Estimates of VE against laboratory-confirmed measles are more accurate because they discriminate measles from other diseases with rash and fever.
Here we investigated VE against self-reported and laboratory-confirmed measles among infants who received an MMR vaccination between 6 and 14 months of age during a measles epidemic in the Netherlands. The epidemic started in May 2013 and lasted until March 2014, with 2700 reported cases [15] . Most cases were unvaccinated orthodox Protestant primary and secondary school-aged children. The epidemic peaked in July 2013, slowed down during the summer holiday, and progressed with a second, lower peak in October 2013. This study was possible because the Dutch Ministry of Health offered an MMR vaccination temporarily to all infants between 6 and 14 months of age who were living in municipalities with MMR vaccination coverage of <90% and to infants in orthodox Protestant families living elsewhere.
METHODS

Study Procedures
We conducted a prospective observational cohort study during the measles epidemic in the Netherlands in 2013-2014. As part of the vaccination campaign, infants between 6 and 14 months of age living in municipalities where coverage with the first dose of MMR vaccine was <90% [16] were invited for an additional or an early MMR vaccination. Infants 6-11 months of age were offered an extra vaccination (and would thus still be eligible for their second MMR vaccination at the age of 14 months), while 12-14-month-old infants were offered an early MMR vaccination as an alternative for the regular time point at 14 months of age. All infants are eligible for another dose of MMR scheduled at 9 years of age.
Approximately 4 weeks after the personal invitation for vaccination, all parents of infants targeted for the early MMR in the 29 municipalities received an invitation to enroll their infant (8) in the study. We could not invite parents of infants in orthodox Protestant families living outside of the 29 targeted municipalities to participate in the study, as religion is not registered in the vaccination registry of the Netherlands. Invitations to participate in the study were sent from week 35 of 2013 up to week 8 of 2014 [17] . Parents of invited infants were asked to register for the study by sending a reply form by regular mail, indicating their e-mail address. Subsequently, they received a link to the online baseline questionnaire. Infants were followed until the end of the epidemic (14 March 2014) . Along the follow-up period, parents were reminded monthly by e-mail to report suspected measles in their infant. When parents did so, they received a second questionnaire and a saliva sampling kit for detection of measles virus. The Central Committee on Research Involving Human Subjects of the Netherlands approved the study.
Data Collection
In the baseline questionnaire, vaccination status was asked, as well as permission to check vaccination status in the national vaccination register. Parents were also asked whether their infant(8) had had measles in the preceding 3 months. In the baseline questionnaire, measles was defined as having a fever (temperature, >38°C), exanthema, and at least 1 of the following symptoms: cough, runny nose, or sore eyes [18] . Other questions, among others, were about sex, day-care center attendance, vaccination status of the parent(8) and sibling (8) , education level of the parent(8), religion, travel history, medication use, comorbidities, breastfeeding, birth weight, and duration of pregnancy. The second questionnaire, which parents received when they reported that their infant had measles, consisted of questions to ascertain symptoms to diagnose self-reported measles.
Laboratory Testing
When parents reported measles in their infant, they were sent a saliva sampling kit, consisting of a tube and a swab. Briefly, we used an immunoglobulin M (IgM) capture enzyme immunoassay specifically designed for the detection of IgM antibodies in oral fluid specimens, according to procedures recommended by the manufacturer (MicroImmune, Hounslow, Middlesex, United Kingdom). The relative specificity and sensitivity of IgM antibody detection in oral fluid as compared to serum is near 100%, as reported by the manufacturer. An infant of whom the parents reported a suspected measles case and from whom the saliva sample tested IgM positive was regarded as a laboratory-confirmed measles case. Laboratory testing was only offered to suspected cases occurring after the baseline questionnaire was completed. Infants for whom it was indicated in the baseline questionnaire that they had had measles in the 3 months before filling out the baseline questionnaire were not offered saliva testing.
Outcomes
We estimated VE against laboratory-confirmed measles and self-reported measles. For VE estimation against laboratory-confirmed measles, the observation time started at the date the baseline questionnaire was filled in and stopped at either the reported date of onset of disease, a second MMR vaccination or the end of the epidemic (14 March 2014), whichever came first. For self-reported measles, the baseline questionnaire included a question about the occurrence of measles in the preceding 3 months. Therefore, we included this 3-month period in the observation time for the outcome of self-reported measles. The start of the observation time for the outcome of self-reported measles was therefore 3 months before the baseline questionnaire, with a minimum at 6 months of age. The end of the observation time for self-reported measles was the date of onset of measles, a second MMR vaccination, or the end of the epidemic, whichever came first.
Statistical Analysis
Infants with a missing address or no permission to check their vaccination status were excluded. We also excluded self-reported cases before the start of the observation time, cases reported 5-12 days after vaccination, and infants who enrolled after their second MMR vaccination or after the epidemic.
VE was calculated as 1 minus the hazard ratio (HR) times 100 [19] . The HR is the ratio of the hazard among vaccinated infants versus the hazard among unvaccinated infants. Kaplan-Meier estimates were used to visualize empirical probabilities of laboratory-confirmed and self-reported measles in vaccinated and unvaccinated infants. A Cox proportional hazard model, which gives a HR as the outcome, assessed the association between vaccination status and the outcomes of laboratory-confirmed measles and self-reported measles. Owing to the varying exposure to measles during an epidemic, we used calendar time as the time scale [20] . Vaccination status was included as a time-varying exposure variable; infants could contribute person-time to both the unvaccinated and vaccinated group. The vaccinated person-time started 12 days after the MMR vaccination. Age was also included as a time-varying variable and was updated every quintile of the observation period.
The following covariates were considered a priori as potential confounders: age, breastfeeding, religion, sibling's vaccination status, day-care center attendance, and travel history. To test which covariates we had to include in our model, we first performed bivariable analyses. The covariate that gave the biggest relative change in the VE (with a minimum of 10%) was included in the model. Subsequently, we added the remaining covariates one by one to the model to check for another change of >10% in the VE. A final model was reached when none of the remaining covariates led to a >10% change. We tested the proportional hazards assumption by using scaled Schoenfeld residuals, where we considered the proportional hazards assumption to be valid with a P value of >.05 for the variables in the final model. Data analysis was conducted using R (version 3.2.0). Cox proportional hazards regression model and KaplanMeier estimates were conducted by using the package survival.
Vaccine
The vaccine administered during this vaccination campaign was the same as the live attenuated MMR vaccine used in the national immunization program (M-M-RVAXPRO; Sanofi Pasteur MSD). This vaccine contains at least 10 3 50% cell culture infectious doses of measles virus Enders' Edmonston strain [21] . (Figure 1) . For 123 infants, the address was not available or parents had indicated that they did not want to receive regular mail from the vaccination registry. We invited 9974 infants to participate in the study, of whom 1866 (19%) agreed and 1304 (13%) filled in the baseline questionnaire. In total, 74 infants (6%) were excluded because parents did not give permission to check their infant's vaccination status, resulting in 1230 eligible infants (12%) for analysis.
RESULTS
Between 13
Characteristics of the cohort are presented in Table 1 . The vaccinated and unvaccinated groups differed considerably. Vaccinated infants were on average 31 days older at enrollment. Unvaccinated infants were more likely to have an unvaccinated sibling or parent and to go to a church with low vaccination coverage. Vaccinated and unvaccinated infants were similar with regard to sex, parents' education level, medication use, comorbidities and birth weight.
In total, 1080 infants were eligible for the analysis of the outcome of laboratory-confirmed measles, after the exclusion of 62 infants with self-reported measles before the start of the observation time, 8 infants who enrolled after their second MMR dose, and 80 infants who enrolled after the measles epidemic (Figure 1 ). During the observation period, 3 vaccinated and 10 unvaccinated laboratory-confirmed cases of measles were reported (Table 2) . Two vaccinated infants were vaccinated at 6 months of age and 1 at 8 months of age. Most cases occurred between September and November 2013 (Figure 2 ). Using Cox proportional hazard modeling, we found an unadjusted HR of 0.06, which corresponds to a VE of 94% (95% confidence interval [CI], 79%-98%; Table 2 ). When we adjusted for confounding (sibling's vaccination status and religion), VE decreased to 71% (95% CI, −72%-95%).
For the analysis of the outcome of self-reported measles, we excluded 12 cases who reported measles 5-12 days following after the early MMR vaccination and 14 cases who reported measles before the start of the observation time. In total, there were 20 vaccinated and 37 unvaccinated self-reported cases of measles (Table 2) , which were reported throughout the observation time ( Figure 3 ). The unadjusted VE for self-reported measles was 67% (95% CI, 40%-82%), and the VE adjusted for religion and sibling vaccination status was 43% (95% CI, −12%-71%; Table 2 ).
DISCUSSION
We showed that infants vaccinated between 6 and 14 months of age had a reduced risk, compared with unvaccinated infants, of laboratory-confirmed measles during an epidemic in the Netherlands, with an unadjusted VE estimate of 94%. This reduction cannot be solely attributed to the effectiveness of the vaccine. Vaccinated infants were probably exposed to measles to a lesser extent than unvaccinated infants, as the latter were more frequently members of the orthodox Protestant community, in which the vaccination coverage is low, and more often had an unvaccinated sibling or parent. When we adjusted for these differences in exposure to measles, the VE against laboratory-confirmed measles decreased to 71%. Owing to low numbers, this estimate was no longer statistically significant.
Unadjusted and adjusted VE estimates against self-reported measles were 67% (95% CI, 40%-82%) and 43% (95% CI, −12%-71%), respectively. The lower VE estimates against self-reported measles, compared with laboratory-confirmed measles, most likely reflect misdiagnosis. First, with an effective vaccine, the presence of cases misdiagnosed as measles results in a lower VE, as relatively more of these cases are present in the vaccinated group [22] . Second, it could be that vaccinating parents may be more likely to erroneously interpret any rash appearance as measles, since they are probably less familiar with measles than parents who are opposed to vaccination. This could lead to a selective increase in false-positive cases among vaccinated infants as compared to unvaccinated infants and hence an underestimation of the VE. Furthermore, most laboratory-confirmed cases occurred from September to October, which coincided with a peak of reported cases during the measles epidemic in the Netherlands [15] , while self-reported cases in our study population occurred constantly over time. Our estimate of VE against the outcome of laboratory-confirmed measles is more accurate, as the laboratory test excludes most rash cases that are not caused by the measles virus.
Our adjusted point estimate of the VE against laboratory-confirmed measles (71%) is adjacent to the lower end of the IQR of the VE (72%-95%) found in a systematic review [13] . This VE estimate was based on 44 MCV estimates, using laboratory confirmation of cases and studies with a cohort or case-control design. However, this estimate was limited to infants vaccinated at 9-11 months of age, while in our study infants 6-8 months old were also included.
A study more comparable in respect to age with our study was conducted during an outbreak in Canada [23] . Deserres et al estimated a VE of 96% (95% confidence interval [CI], 72%-99%) against clinical measles for infants 6-11 months of age. Our adjusted estimate against laboratory-confirmed measles borders the lower value of the 95% CI, despite the inclusion of infants vaccinated between 12-14 months of age in our study. However, the Canadian study assumed comparable levels of exposure to measles between the vaccinated and unvaccinated infants, whereas we tried to include exposure to measles in our model through adjustment for surrogates of exposure to measles.
Our results indicate that exposure to measles as assessed through such proxies differed between vaccinated and unvaccinated infants and that it influenced the VE estimates. Adjustment of the VE with surrogates of measles exposure led to lower VE estimates for both self-reported and laboratory-confirmed measles. This was in line with our expectations, given that the measles epidemic in the Netherlands largely took place among unvaccinated orthodox Protestant children [15] , who live in sociogeographic clusters [24] . Thus, we think that exposure to measles is an important factor to take into account in the estimation of VE in observational studies, especially given that parents' choice to vaccinate also depends on the choices of their social network [25] and that, if the networks of the parents' children overlap, clusters of unvaccinated children emerge [26] .
To our knowledge, only one randomized clinical trial has been conducted to estimate the measles efficacy of MCV in children vaccinated at <9 months of age in an outbreak setting [27] . Because infants were randomly assigned to be vaccinated, different levels of exposure to measles can most likely be ruled out in this clinical trial. Martins et al followed 1333 infants aged 4.5 months, of whom 441 were vaccinated, for 5 months and found a VE of 94% (95% CI, 74%-98%) against laboratory-confirmed measles. In comparison with our estimate this is substantially higher, all the more since infants were vaccinated at 4.5 months of age. It is, however, important to note that in this trial the Edmonston Zagreb vaccine was used, which has been reported to have a higher immunogenicity in infants than other vaccines [27, 28] .
The main limitation of our study is that infants were not randomly assigned to receive or not receive early MMR vaccination but self-selected whether to vaccinate, and therefore we studied different groups in respect to exposure to measles. We have addressed this difference in exposure to measles by correcting for surrogates, but residual confounding cannot be excluded. Another limitation of our study is the low response rate and small number of cases. As a result, we did not have sufficient statistical power to find precise VE estimates, which may account for some of the variance between our VE estimates and previous estimates in literature. In addition, the small number of cases limited us to study differences in the severity of disease between vaccinated and unvaccinated cases and to stratify the results by age at vaccination. In a subgroup analysis of infants vaccinated at <9 months of age and unvaccinated infants enrolling before 9 months of age, we found an unadjusted VE against laboratory-confirmed measles of 81% (95% CI, 7.6%-96%).
Since infants are at the greatest risk during recent outbreaks in Europe and as they are at the highest risk for complications, too, it is important to protect them during outbreaks. Recently, a study by our group concluded that MMR vaccine is safe to protect infants aged 6-14 months of age [29] . The trade-off, however, is a lower VE, leaving relatively more vaccinated infants susceptible. This lower VE can be largely voided by the additional measles vaccination recommended in the World Health Organization schedule, given that the majority of children who did not develop sufficient antibodies after their first measles vaccination will develop protective antibody levels after their second measles vaccination [11] .
However, a concern is that vaccinated infants who received their first MCV vaccination at 6 months of age-and despite subsequent secondary and tertiary doses-had lower levels of humoral responses at 7-10 years of age, compared with those who received the first dose of MMR at 12 months [30] . This blunting could be associated with the interference of maternal antibodies and an immature immunity. That this effect may be of clinical relevance is suggested by first results of an outbreak investigation among students in Canada [31] . Here relatively more twice-vaccinated cases were reported who received their first MMR dose at 12 months of age than twice-vaccinated cases who received their first MMR at 15 months of age.
In conclusion, MMR vaccinated infants between 6-14 months of age were at lower risk of measles than unvaccinated infants. However, part of the effect was caused by the herd immunity yielded by the regular national immunization program in the Netherlands; vaccinated infants were more likely to be surrounded by vaccinated individuals and were therefore to a lesser extent exposed to measles. Our VE estimates, adjusted for exposure to measles through the use of proxies, suggest that the early MMR vaccination campaign in the Netherlands was effective, but precise estimates are lacking, and further research on VE at a young age is required. In the meantime, given the high disease burden in infants <14 months of age and the early loss of maternal protection, early MMR vaccination is recommended when the risk of measles is high. 
Notes
